DUBLIN – Bavarian Nordic A/S has landed another vaccine development deal with Johnson & Johnson, an alliance worth up to $879 million covering the use of its modified vaccinia ankara (MVA-BN) technology in the development of vaccines against HIV-1 and hepatitis B virus (HBV). Kvistgaard, Denmark-based Bavarian Nordic is receiving $10 million of the total as an up-front payment and another $33 million as an equity investment.